NAMSW
NewAmsterdam Pharma Company N.V. WarrantNASDAQ
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
—
Beta
0.03
52W High
$29.99
52W Low
$7.16
50-Day MA
$21.10
200-Day MA
$20.65
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About NewAmsterdam Pharma Company N.V. Warrant
NewAmsterdam Pharma Company N.V. is an innovative clinical-stage biopharmaceutical firm dedicated to developing groundbreaking therapeutics for cardiometabolic diseases, with a primary focus on dyslipidemia—a key contributor to cardiovascular risk. The company employs a rigorous scientific methodology alongside a robust R&D framework, positioning itself strategically for potential regulatory approval of its unique drug candidates. By addressing substantial unmet medical needs within this critical therapeutic area, NewAmsterdam seeks to significantly enhance patient outcomes while driving long-term value for shareholders, making it a compelling investment opportunity in the biopharmaceutical sector.
Fundamentals
| Revenue (TTM) | $22.50M |
| Gross Profit (TTM) | $22.50M |
| EBITDA | $-225.46M |
| Operating Margin | -206188.00% |
| Return on Equity | -28.30% |
| Return on Assets | -17.30% |
| Revenue/Share (TTM) | $0.19 |
| Book Value | $5.97 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -99.80% |
| Shares Outstanding | 0 |
| Float | $71.47M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
HV 10-Day
152.08%
HV 20-Day
116.44%
HV 30-Day
108.07%
HV 60-Day
101.52%
HV Rank
82.9%
Volatility is currently expanding
Data last updated: 5/5/2026